Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 11 2 2022
medline: 11 3 2022
entrez: 10 2 2022
Statut: ppublish

Résumé

A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort. This multicenter international retrospective study (United States, Europe, New Zealand) included consecutive patients with CVT treated with oral anticoagulation from January 2015 to December 2020. We abstracted demographics and CVT risk factors, hypercoagulable labs, baseline imaging data, and clinical and radiological outcomes from medical records. We used adjusted inverse probability of treatment weighted Cox-regression models to compare recurrent cerebral or systemic venous thrombosis, death, and major hemorrhage in patients treated with warfarin versus DOACs. We performed adjusted inverse probability of treatment weighted logistic regression to compare recanalization rates on follow-up imaging across the 2 treatments groups. Among 1025 CVT patients across 27 centers, 845 patients met our inclusion criteria. Mean age was 44.8 years, 64.7% were women; 33.0% received DOAC only, 51.8% received warfarin only, and 15.1% received both treatments at different times. During a median follow-up of 345 (interquartile range, 140-720) days, there were 5.68 recurrent venous thrombosis, 3.77 major hemorrhages, and 1.84 deaths per 100 patient-years. Among 525 patients who met recanalization analysis inclusion criteria, 36.6% had complete, 48.2% had partial, and 15.2% had no recanalization. When compared with warfarin, DOAC treatment was associated with similar risk of recurrent venous thrombosis (aHR, 0.94 [95% CI, 0.51-1.73]; In patients with CVT, treatment with DOACs was associated with similar clinical and radiographic outcomes and favorable safety profile when compared with warfarin treatment. Our findings need confirmation by large prospective or randomized studies.

Sections du résumé

BACKGROUND
A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort.
METHODS
This multicenter international retrospective study (United States, Europe, New Zealand) included consecutive patients with CVT treated with oral anticoagulation from January 2015 to December 2020. We abstracted demographics and CVT risk factors, hypercoagulable labs, baseline imaging data, and clinical and radiological outcomes from medical records. We used adjusted inverse probability of treatment weighted Cox-regression models to compare recurrent cerebral or systemic venous thrombosis, death, and major hemorrhage in patients treated with warfarin versus DOACs. We performed adjusted inverse probability of treatment weighted logistic regression to compare recanalization rates on follow-up imaging across the 2 treatments groups.
RESULTS
Among 1025 CVT patients across 27 centers, 845 patients met our inclusion criteria. Mean age was 44.8 years, 64.7% were women; 33.0% received DOAC only, 51.8% received warfarin only, and 15.1% received both treatments at different times. During a median follow-up of 345 (interquartile range, 140-720) days, there were 5.68 recurrent venous thrombosis, 3.77 major hemorrhages, and 1.84 deaths per 100 patient-years. Among 525 patients who met recanalization analysis inclusion criteria, 36.6% had complete, 48.2% had partial, and 15.2% had no recanalization. When compared with warfarin, DOAC treatment was associated with similar risk of recurrent venous thrombosis (aHR, 0.94 [95% CI, 0.51-1.73];
CONCLUSIONS
In patients with CVT, treatment with DOACs was associated with similar clinical and radiographic outcomes and favorable safety profile when compared with warfarin treatment. Our findings need confirmation by large prospective or randomized studies.

Identifiants

pubmed: 35143325
doi: 10.1161/STROKEAHA.121.037541
doi:

Substances chimiques

Anticoagulants 0
Warfarin 5Q7ZVV76EI
Dabigatran I0VM4M70GC

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

728-738

Commentaires et corrections

Type : CommentIn

Auteurs

Shadi Yaghi (S)

Department of Neurology, Brown University, Providence, RI (S.Y., L.S., C.S., N.K., S.E.J., A.C., S.C., K.F.).

Liqi Shu (L)

Department of Neurology, Brown University, Providence, RI (S.Y., L.S., C.S., N.K., S.E.J., A.C., S.C., K.F.).

Ekaterina Bakradze (E)

Department of Neurology, University of Alabama at Birmingham (E.B.).

Setareh Salehi Omran (S)

Department of Neurology, University of Colorado School of Medicine, Aurora (S.S.O.).

James A Giles (JA)

Department of Neurology, Washington University, Saint Louis, MO (J.A.G., J.Y.A.).

Jordan Y Amar (JY)

Department of Neurology, Washington University, Saint Louis, MO (J.A.G., J.Y.A.).

Nils Henninger (N)

Department of Neurology (N.H., M.E.), University of Massachusetts, Worcester.
Department of Psychiatry (N.H.), University of Massachusetts, Worcester.

Marwa Elnazeir (M)

Department of Neurology (N.H., M.E.), University of Massachusetts, Worcester.

Ava L Liberman (AL)

Department of Neurology, Weill Cornell Medical Center, NY (A.L.L.).

Khadean Moncrieffe (K)

Department of Neurology, Montefiore Medical Center, NY (K.M., J.L.).

Jenny Lu (J)

Department of Neurology, Montefiore Medical Center, NY (K.M., J.L.).

Richa Sharma (R)

Department of Neurology, Yale University, New Haven, CT (R.S., Y.C., A.S.Z., A.d.H.).

Yee Cheng (Y)

Department of Neurology, Yale University, New Haven, CT (R.S., Y.C., A.S.Z., A.d.H.).

Adeel S Zubair (AS)

Department of Neurology, Yale University, New Haven, CT (R.S., Y.C., A.S.Z., A.d.H.).

Alexis N Simpkins (AN)

Department of Neurology, University of Florida, Gainesville (A.N.S., G.T.L., J.C.K., D.P.).

Grace T Li (GT)

Department of Neurology, University of Florida, Gainesville (A.N.S., G.T.L., J.C.K., D.P.).

Justin Chi Kung (JC)

Department of Neurology, University of Florida, Gainesville (A.N.S., G.T.L., J.C.K., D.P.).

Dezaray Perez (D)

Department of Neurology, University of Florida, Gainesville (A.N.S., G.T.L., J.C.K., D.P.).

Mirjam Heldner (M)

Department of Neurology, Inselspital Universitätsspital, Bern, Switzerland (M.H., A.S., D.S., B.S.).

Adrian Scutelnic (A)

Department of Neurology, Inselspital Universitätsspital, Bern, Switzerland (M.H., A.S., D.S., B.S.).

David Seiffge (D)

Department of Neurology, Inselspital Universitätsspital, Bern, Switzerland (M.H., A.S., D.S., B.S.).

Bernhard Siepen (B)

Department of Neurology, Inselspital Universitätsspital, Bern, Switzerland (M.H., A.S., D.S., B.S.).

Aaron Rothstein (A)

Department of Neurology, University of Pennsylvania, Philadelphia, PA (A.R., O.K., D.D.).

Ossama Khazaal (O)

Department of Neurology, University of Pennsylvania, Philadelphia, PA (A.R., O.K., D.D.).

David Do (D)

Department of Neurology, University of Pennsylvania, Philadelphia, PA (A.R., O.K., D.D.).

Sami Al Kasab (SA)

Department of Neurology (S.A.K., L.A.R.), Medical University of South Carolina, Charleston.
Department of Neurosurgery (S.A.K.), Medical University of South Carolina, Charleston.

Line Abdul Rahman (LA)

Department of Neurology (S.A.K., L.A.R.), Medical University of South Carolina, Charleston.

Eva A Mistry (EA)

Department of Neurology and Rehabilitation Medicine, University of Cincinnati (E.A.M., P.K., Y.A., B.C.).

Deborah Kerrigan (D)

Department of Neurology, Vanderbilt University, Nashville, TN (D.K., H.L.).

Hayden Lafever (H)

Department of Neurology, Vanderbilt University, Nashville, TN (D.K., H.L.).

Thanh N Nguyen (TN)

Department of Neurology, Boston University School of Medicine, MA (T.N.N., P.K., H.A.).

Piers Klein (P)

Department of Neurology and Rehabilitation Medicine, University of Cincinnati (E.A.M., P.K., Y.A., B.C.).
Department of Neurology, Boston University School of Medicine, MA (T.N.N., P.K., H.A.).

Hugo Aparicio (H)

Department of Neurology, Boston University School of Medicine, MA (T.N.N., P.K., H.A.).

Jennifer Frontera (J)

Department of Neurology, New York University, NY (J.F., L.K., S.A.).

Lindsey Kuohn (L)

Department of Neurology, New York University, NY (J.F., L.K., S.A.).

Shashank Agarwal (S)

Department of Neurology, New York University, NY (J.F., L.K., S.A.).

Christoph Stretz (C)

Department of Neurology, Brown University, Providence, RI (S.Y., L.S., C.S., N.K., S.E.J., A.C., S.C., K.F.).

Narendra Kala (N)

Department of Neurology, Brown University, Providence, RI (S.Y., L.S., C.S., N.K., S.E.J., A.C., S.C., K.F.).

Sleiman El Jamal (S)

Department of Neurology, Brown University, Providence, RI (S.Y., L.S., C.S., N.K., S.E.J., A.C., S.C., K.F.).

Alison Chang (A)

Department of Neurology, Brown University, Providence, RI (S.Y., L.S., C.S., N.K., S.E.J., A.C., S.C., K.F.).

Shawna Cutting (S)

Department of Neurology, Brown University, Providence, RI (S.Y., L.S., C.S., N.K., S.E.J., A.C., S.C., K.F.).

Han Xiao (H)

Department of Biostatistics, University of California Santa Barbara (H.X.).

Adam de Havenon (A)

Department of Neurology, Yale University, New Haven, CT (R.S., Y.C., A.S.Z., A.d.H.).

Varsha Muddasani (V)

Department of Neurology, University of Utah, Salt Lake City (V.M.).

Teddy Wu (T)

Department of Neurology, Christchurch hospital, New Zealand (T.W., D.W.).

Duncan Wilson (D)

Department of Neurology, Christchurch hospital, New Zealand (T.W., D.W.).

Amre Nouh (A)

Department of Neurology, Hartford Hospital, CT (A.N., S.D.A.).

Syed Daniyal Asad (SD)

Department of Neurology, Hartford Hospital, CT (A.N., S.D.A.).

Abid Qureshi (A)

Department of Neurology, University of Kansas, Kansas City (A.Q., J.M.).

Justin Moore (J)

Department of Neurology, University of Kansas, Kansas City (A.Q., J.M.).

Yasmin Aziz (Y)

Department of Neurology and Rehabilitation Medicine, University of Cincinnati (E.A.M., P.K., Y.A., B.C.).

Bryce Casteigne (B)

Department of Neurology and Rehabilitation Medicine, University of Cincinnati (E.A.M., P.K., Y.A., B.C.).

Muhib Khan (M)

Department of Neurology, Spectrum Health, Michigan State University, Grand Rapids (M.K., Y.C.).

Yao Cheng (Y)

Department of Neurology, Spectrum Health, Michigan State University, Grand Rapids (M.K., Y.C.).

Brian Mac Grory (B)

Department of Neurology, Duke University, Durham, NC (B.M.G., M.W., D.R.).

Martin Weiss (M)

Department of Neurology, Duke University, Durham, NC (B.M.G., M.W., D.R.).

Dylan Ryan (D)

Department of Neurology, Duke University, Durham, NC (B.M.G., M.W., D.R.).

Maria Cristina Vedovati (MC)

Department of Medicine and Surgery, University of Perugia, Italy (M.C.V.).

Maurizio Paciaroni (M)

Neurology - Stroke Unit, IRCCS MultiMedica, Milano, Italy (M.P.).

James E Siegler (JE)

Department of Neurology, Cooper University, Camden, NJ (J.E.S., S.K., S.Y.).

Scott Kamen (S)

Department of Neurology, Cooper University, Camden, NJ (J.E.S., S.K., S.Y.).

Siyuan Yu (S)

Department of Neurology, Cooper University, Camden, NJ (J.E.S., S.K., S.Y.).

Christopher R Leon Guerrero (CR)

Department of Neurology, George Washington University, District of Columbia (C.R.L.G., E.A.).

Eugenie Atallah (E)

Department of Neurology, George Washington University, District of Columbia (C.R.L.G., E.A.).

Gian Marco De Marchis (GM)

Department of Neurology, University Hospital Basel and University of Basel, Switzerland (G.M.D.M., T.D.).

Alex Brehm (A)

Department of interventional and diagnostic Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Switzerland (A.B., M.P.).

Tolga Dittrich (T)

Department of Neurology, University Hospital Basel and University of Basel, Switzerland (G.M.D.M., T.D.).

Marios Psychogios (M)

Department of interventional and diagnostic Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Switzerland (A.B., M.P.).

Ronald Alvarado-Dyer (R)

Department of Neurology, University of Chicago, IL (R.A.-D., T.K.-H., S.P.).

Tareq Kass-Hout (T)

Department of Neurology, University of Chicago, IL (R.A.-D., T.K.-H., S.P.).

Shyam Prabhakaran (S)

Department of Neurology, University of Chicago, IL (R.A.-D., T.K.-H., S.P.).

Tristan Honda (T)

Department of Neurology, University of California at Los Angeles (T.H., D.S.L.).

David S Liebeskind (DS)

Department of Neurology, University of California at Los Angeles (T.H., D.S.L.).

Karen Furie (K)

Department of Neurology, Brown University, Providence, RI (S.Y., L.S., C.S., N.K., S.E.J., A.C., S.C., K.F.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH